SCHEMBL4085564

SCHEMBL4085564

O=C(O)c1c(-c2cccs2)csc1NC(=O)C12CC3CC(CC1C3)C2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.56
KMT2A Q03164 3/20 0.56
LMNA P02545 2/20 0.56
MEN1 O00255 2/20 0.56
USP2 O75604 1/20 0.56
CNR2 P34972 1/20 0.46
TP53 P04637 4/20 0.42
POLB P06746 3/20 0.42
HSD11B1 P28845 1/20 0.40
PPARG P37231 1/20 0.40
NCOA2 Q15596 1/20 0.40
NCOA1 Q15788 1/20 0.40
HIF1A Q16665 1/20 0.40
ADORA1 P30542 1/20 0.40
KDM4E B2RXH2 5/20 0.40
TDP1 Q9NUW8 4/20 0.40
HPGD P15428 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
HTT P42858 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091492 0.86 CNR2 (0.62) MAPTKMT2ALMNAMEN1USP2
SCHEMBL3801843 0.86 CNR2 (0.62) MAPTKMT2ALMNAMEN1USP2
SCHEMBL4095706 0.85 TP53 (0.64) MAPTLMNAUSP2CNR2TP53
SCHEMBL4083976 0.85 CNR2 (0.55) MAPTKMT2ALMNAMEN1USP2
SCHEMBL4089760 0.82 KMT2A (0.46) MAPTKMT2AMEN1USP2CNR2
SCHEMBL3743041 0.78 CNR2 (0.46) MAPTCNR2HSD11B1ADORA1
SCHEMBL4086759 0.77 CNR2 (0.40) CNR2HSD11B1ADORA1MAPK10
SCHEMBL3799426 0.77 CNR2 (0.40) CNR2HSD11B1ADORA1MAPK10
SCHEMBL4096379 0.75 CNR2 (0.41) CNR2HSD11B1ADORA1MAPK10
SCHEMBL3646676 0.73 CNR2 (0.55) CNR2HSD11B1ADORA1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 MAPT 2527/4885KMT2A 2505/4885LMNA 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.